EyePoint Pharmaceuticals Inc [EYPT] stock is trading at $10.54, up 14.81%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The EYPT shares have gain 19.64% over the last week, with a monthly amount glided 85.56%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
EyePoint Pharmaceuticals Inc [NASDAQ: EYPT] stock has seen the most recent analyst activity on June 17, 2025, when RBC Capital Mkts initiated its Outperform rating and assigned the stock a price target of $28. Previously, Citigroup started tracking the stock with Buy rating on January 07, 2025, and set its price target to $33. On October 16, 2024, Scotiabank initiated with a Sector Outperform rating. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $15 on August 28, 2024. JP Morgan initiated its recommendation with a Overweight and recommended $35 as its price target on January 22, 2024. Mizuho started tracking with a Buy rating for this stock on November 02, 2023, and assigned it a price target of $20. In a note dated April 21, 2023, Robert W. Baird initiated an Outperform rating and provided a target price of $33 on this stock.
EyePoint Pharmaceuticals Inc [EYPT] stock has fluctuated between $3.91 and $13.98 over the past year. Currently, Wall Street analysts expect the stock to reach $26 within the next 12 months. EyePoint Pharmaceuticals Inc [NASDAQ: EYPT] shares were valued at $10.54 at the most recent close of the market. An investor can expect a potential return of 146.68% based on the average EYPT price forecast.
Analyzing the EYPT fundamentals
EyePoint Pharmaceuticals Inc [NASDAQ:EYPT] reported sales of 56.04M for the trailing twelve months, which represents a growth of 109.29%. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -2.88%, Pretax Profit Margin comes in at -2.62%, and Net Profit Margin reading is -2.62%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is -0.54 and Total Capital is -0.5. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.36 points at the first support level, and at 8.17 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.25, and for the 2nd resistance point, it is at 11.95.
Ratios To Look Out For
For context, EyePoint Pharmaceuticals Inc’s Current Ratio is 7.85. Further, the Quick Ratio stands at 7.79, while the Cash Ratio is 2.04. Considering the valuation of this stock, the price to sales ratio is 12.94, the price to book ratio is 2.43.
Transactions by insiders
Recent insider trading involved Zaderej Karen L., Director, that happened on May 19 ’25 when 5000.0 shares were purchased. Director, Zaderej Karen L. completed a deal on May 16 ’25 to buy 5000.0 shares. Meanwhile, Director Zaderej Karen L. bought 5000.0 shares on May 15 ’25.
